A randomized,parallel-controlled clinical study of Tibetan medicine in the treatment of COVID-19 infection in plateau region
GESANG Yun-dan
DUO Jie-tai
ZHANG Qiong-wen
PINGCUO Duo-ji
WANG Bao
SUOLANG Ren-qing
SANG Dan
SHEN Yan-ru
LI Yan-jun
MINGJI Cuo-mu
DANSONG Zha-ba
TANG Jian-yuan
CHEN Wei-wu
Abstract：Objective:To observe the effects of Tibetan medicine on the negative nucleic acid conversion rate and symptom resolution rate in mild or asymptomatic COVID-19 patients in plateau area.Methods:A total of 629 patients were randomly assigned to three groups:Tibetan medicine group 1(Cuitang granules+Liugan pills),Tibetan medicine group 2(Liugan pills)and conventional treatment group(antiviral drug Azfudine tablets),using random number table.Following treatment,negative nucleic acid conversion rate and symptom resolution rate were evaluated.Results:Tibetan medicine group 2 has a significant advantage in reducing the time for nucleic acid to turn negative;both group 1 and group 2 of Tibetan medicine have better efficacy in symptom disappearance rate than the conventional treatment group(P<0.05);the hospitalization time of patients in Tibetan medicine group 2 is shorter than that of Tibetan medicine group 1 and the conventional treatment group,showing certain advantages.Conclusion:Tibetan medicine has certain advantages in relieving symptoms caused by COVID-19 infection such as cough,headache and sore throat.It can shorten the length of hospital stay of patients and improve the negative conversion rate of nucleic acid.
Keywords：plateau regionTibetan medicineclinical research
Publication Date：2025-05-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：7( 939-945 )